In one paragraphArticle in Nucleic acids research, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from itWhat it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
2 · The registryThe trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
3 · Its place in the literatureWho cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
4 · The recordCorrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
5 · Who and what moneyAuthors and funding
17 authors.
Alexander A GirgisDepartment of Biomedical Engineering, Johns Hopkins University, Baltimore, MD, 21218, United States.ORCID 0000-0002-4706-5480 Amanda L HuffDepartment of Oncology, Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University, Baltimore, MD, 21231, United States.ORCID 0000-0002-8423-8985 Emily Davis-MarcisakDepartment of Biomedical Engineering, Johns Hopkins University, Baltimore, MD, 21218, United States.ORCID 0000-0001-8624-1013 Theron PalmerDepartment of Biomedical Engineering, Johns Hopkins University, Baltimore, MD, 21218, United States.ORCID 0000-0002-8806-4062 Hanzhi WangDepartment of Biomedical Engineering, Johns Hopkins University, Baltimore, MD, 21218, United States.ORCID 0009-0001-4577-0864 Luciane T KagoharaDepartment of Oncology, Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University, Baltimore, MD, 21231, United States.ORCID 0000-0003-1706-0950 Janelle M MontagneDepartment of Oncology, Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University, Baltimore, MD, 21231, United States.ORCID 0000-0002-8113-1373 Dmitrijs LvovsInstitute for Genome Sciences, University of Maryland School of Medicine, Baltimore, MD, 21201, United States.ORCID 0009-0003-2152-6853 Ludmila DanilovaDepartment of Oncology, Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University, Baltimore, MD, 21231, United States.ORCID 0000-0003-2813-3094 Alexander V FavorovDepartment of Oncology, Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University, Baltimore, MD, 21231, United States.ORCID 0000-0003-2595-1091 Jonathan SchneckDepartment of Pathology, Johns Hopkins University, Baltimore, MD, 21287, United States.
Clifton O Bingham IiiDivision of Rheumatology, Department of Medicine, The Johns Hopkins University School of Medicine, Baltimore, MD, 21202, United States.ORCID 0000-0002-4752-5029 Erika DarrahDivision of Rheumatology, Department of Medicine, The Johns Hopkins University School of Medicine, Baltimore, MD, 21202, United States.ORCID 0000-0003-1119-0279 Elizabeth M JaffeeDepartment of Oncology, Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University, Baltimore, MD, 21231, United States.ORCID 0000-0003-3841-6549 Neeha ZaidiDepartment of Oncology, Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University, Baltimore, MD, 21231, United States.ORCID 0000-0002-0094-0049 Bahman AfsariDepartment of Oncology, Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University, Baltimore, MD, 21231, United States.ORCID 0000-0001-8717-7199 Elana J FertigDepartment of Biomedical Engineering, Johns Hopkins University, Baltimore, MD, 21218, United States.ORCID 0000-0003-3204-342X Funding
Translational Research Central ServicesP30CA006973 · NCI · JOHNS HOPKINS UNIVERSITY · PI ALAN KEITH MEEKER · 1985 to 2026
$208.6MTumor Antigens for Individual Signatures and TherapyP50CA062924 · NCI · JOHNS HOPKINS UNIVERSITY · PI THOMPSON, ELIZABETH D · 1993 to 2022
$54.6MTransforming Human Pancreatic Cancer Into An Immunologic DiseaseP01CA247886 · NCI · JOHNS HOPKINS UNIVERSITY · PI AZAD, NILOFER S. · 2021 to 2025
$12.7MSample Processing and Immunoassay Research CoreP30AR070254 · NIAMS · JOHNS HOPKINS UNIVERSITY · PI CLIFTON O BINGHAM, Antony Rosen · 2016 to 2026
$8.9MPhenotype-Specific Immune Responses in the Systemic VasculitidesP30AR053503 · NIAMS · JOHNS HOPKINS UNIVERSITY · PI SOLOSKI, MARK J · 2006 to 2015
$6.4MSingle-cell and imaging data integration software to spatially resolve the tumor microenvironmentU01CA253403 · NCI · JOHNS HOPKINS UNIVERSITY · PI FERTIG, ELANA · 2020 to 2022
$1.2MNeoantigen-Targeted Vaccines in Combination with Immune Checkpoint Inhibitors for Pancreatic CancerK08CA248624 · NCI · JOHNS HOPKINS UNIVERSITY · PI ZAIDI, NEEHA · 2021 to 2025
$1.1MComprehensive Analysis and Multi-Omics Data Integration for Cancer-Related StudiesR50CA243627 · NCI · JOHNS HOPKINS UNIVERSITY · PI Ludmila Danilova · 2019 to 2026
$975kT cell mechanisms of immunotherapy response in pancreatic ductal adenocarcinomaF31CA250135 · NCI · JOHNS HOPKINS UNIVERSITY · PI DAVIS, EMILY · 2021 to 2022
$74kArthritis Discovery FundCamille Julia Morgan Arthritis Research and Education FundCancer FoundationIntramural Research Program of the NIHJerome. L. Greene FoundationJohns Hopkins Medical Institutions FY24Lustgarten FoundationMaryland Cancer Moonshot ResearchNational Institute of HealthNCI NIH HHS F31 CA250135NCI NIH HHS F31CA250135NCI NIH HHS F32CA271470-01NCI NIH HHS K08 CA248624NCI NIH HHS P01 CA247886NCI NIH HHS P01CA247886NCI NIH HHS P30CA006973NCI NIH HHS P50CA062924NCI NIH HHS R50 CA243627NCI NIH HHS R50CA243627NCI NIH HHS U01 CA253403NCI NIH HHS U01CA253403NIAMS NIH HHS P30AR053503NIAMS NIH HHS P30AR070254NIH HHSStand Up To Cancer
6 · The paper itselfAbstract
A continued challenge in the analysis of adaptive immune receptor repertoires (AIRRs) is the prediction of antigen reactivity from primary sequence data. Many algorithms infer antigen-specific responses by measuring sequence similarity between receptors. Similarity is often scored using tools for protein alignment such as the BLOSUM matrices. However, these metrics were designed to identify homology in genomic proteins, not VDJ-recombined immune receptors. Comparison of these metrics against other approaches is underexplored. We used matrix factorization to make physiochemical-based alternatives which may improve performance. We evaluated these metrics by clustering 383 simulated and biological repertoires using traditional and physiochemical-based scoring matrices. While physiochemical and traditional scoring had similar efficacy, the membership of antigen-specific clusters varied. Lastly, we inferred antigen-specific immune responses in pancreatic cancer and rheumatoid arthritis. Results varied depending on the matrix used, emphasizing a poor consensus among methods. Despite equivocal performance, physiochemical factors can increase the interpretability of clustered repertoires. These results suggest that analysts must carefully consider characteristics of sequence similarity measures to apply the most appropriate methods to their data. We facilitate further exploration of scoring metrics by centralizing AIRR clustering and physiochemical sequence characterization in a software tool called Homolig (Homol-Ig) associated with our analyses.
Indexed as
Receptors, ImmunologicAdaptive ImmunityAlgorithmsAntigensArthritis, RheumatoidCluster AnalysisHumansPancreatic NeoplasmsAntigensReceptors, Immunologic
Identifiers
PMID41261860
PMCPMC12630133
What OpenQuestion holds
Textmetadata
Read underepoch 390